POS0693 EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS IN REAL-LIFE SETTING: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC, PROSPECTIVE COHORT
نویسندگان
چکیده
Background: LN is still a severe manifestation of Systemic lupus erythematosus (SLE) and multitarget therapy needed to control the disease especially in refractory cases. Objectives: To evaluate renal response SLE patients with glomerulonephritis (GN) treated Belimumab real-life setting. Methods: Patients proteinuria >0.5 g/24 h and/or active sediment at baseline enrolled multicentre Italian cohort (BeRLiSS study), monthly iv 10 mg/kg plus standard care were considered this study. Complete (CRR ) was defined as <0.5 h, estimated glomerular filtration rate (eGFR)≥90ml/min/1.73m 2 no rescue therapy. Primary efficacy (PERR ≤0.7 eGFR ≥60ml/min/1.73m Prevalence predictive factors CRR PERR 12 24 months after initiation analyzed by multivariate logistic regression analysis. Results: A total 91 study, 79 female, mean age 40.51±9.03 years, duration 12.18±8.15 median follow-up time 22 months. Twenty had ≥0.5 <1 g/day, 17 ≥1 <2 13 ≥2 g/day. started GN onset 20 (22%) flare all other Seventy-five underwent biopsy: 1 class I, 4 II, 14 III, 47 IV 9 V. Baseline serum creatinine 82.44±29.26 umol/L; 15 showed eGFR<60ml/min/1.73m baseline. Immunosuppresants taken 70 (76.9%) patients: micofenolate, azathioprine 5 ciclosporine. Sixty (65.9%) on antimalarials. During 34 (37.4%) achieved CRR. Among them (14.7%) relapsed 29 (85.3%) maintained remission. Mean 9.71±5.91 High levels negative independent predictor 6 (OR 0.044 CI95% 0.006-0.320 p=0.002 OR 0.232 0.091-0.596 0.029 0.002-0.556 p=0.019 0.056 0.009-0.327 p=0.001 ). response. Renal strong factor Conclusion: an effective add-on treatment practice Disclosure Interests: None declared
منابع مشابه
Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus
Practicing physicians have requested efficacy and safety data for belimumab, when used with specific systemic lupus erythematosus (SLE) medications. This was a post hoc analysis of pooled efficacy and safety data from patients who received belimumab 10 mg/kg plus standard of care (SoC) or placebo (SoC) in two Phase III, randomized trials, BLISS-52 and BLISS-76. Patients were categorized into fo...
متن کاملEfficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
OBJECTIVE To evaluate the efficacy and safety of rituximab in a randomized, double-blind, placebo-controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids. METHODS Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182....
متن کاملEfficacy and Safety of Rituximab in patients with Neuromyelitis Optica Spectrum Disorders: A prospective observation in Iranian Cases.
متن کامل
Real life experience on the effect of Belimumab in patients with active systemic lupus
INTRODUCTION To evaluate real life experience on the effect of Belimumab in patients with active systemic lupus erythematosus. CASE PRESENTATION Twenty patinets with musclesketal symptoms were evaluated, three were discontinued for different resons and seventeen completed eight injections of Belimumab during a six month period. A fatigue score was also evaluated at the same time. DISCUSSION...
متن کاملa comparison of teachers and supervisors, with respect to teacher efficacy and reflection
supervisors play an undeniable role in training teachers, before starting their professional experience by preparing them, at the initial years of their teaching by checking their work within the proper framework, and later on during their teaching by assessing their progress. but surprisingly, exploring their attributes, professional demands, and qualifications has remained a neglected theme i...
15 صفحه اولذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the Rheumatic Diseases
سال: 2021
ISSN: ['1468-2060', '0003-4967']
DOI: https://doi.org/10.1136/annrheumdis-2021-eular.1757